Upcoming Medical Policies BlueCross BlueShield of Tennessee |
Each medical policy listed below will become effective on the date indicated, and will be included in the Medical Policy Manual for BlueCross BlueShield of Tennessee on that effective date.
Medical policies are developed using an evidence-based evaluation process. The medical evidence used in this process comes from several sources, including independent medical technology review organizations, the peer reviewed medical literature, and opinions from appropriate network specialists. All Medical Policies are reviewed by a panel of internal and external physicians before being adopted by the company.
Topics due to be included in the Medical Policy Manual on 10/31/2024
Topics due to be included in the Medical Policy Manual on 12/03/2024
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Topics due to be included in the Medical Policy Manual on 10/31/2024:
Delandistrogene moxeparvovec-rokl (Elevidys®)
Fam-trastuzumab Deruxtecan-nxki (Enhertu®)
Lisocabtagene Maraleucel (Breyanzi®)
Tocilizumab (Actemra®); Tocilizumab-bavi (Tofidence™); Tocilizumab-aazg (Tyenne®)
Topics due to be included in the Medical Policy Manual on 12/03/2024
Bevacizumab Products (Avastin®; Mvasi® ; Zirabev™; Alymsys®; Vegzelma™, Avzivi®)
Temozolomide (Temodar®), temozolomide
Trastuzumab Products (Herceptin®, Ontruzant®, Herzuma®, Ogivri®, Trazimera™, Kanjinti™, Hercessi™)
Ustekinumab (Stelara®); Ustekinumab-auub (Wezlana™)
Last Review Date: 9/30/2024
Please reference the policy name in your comments.
To submit comments about the upcoming Medical policies:
Click the “Medical Policy Comments” above or click here: Comments or Feedback.Please reference the policy name in your comments.
To submit comments about the upcoming Pharmacy policies:
Click the “Pharmacy Policy Comments” above or click here: Comments or Feedback.Comments can also be mailed to:
BlueCross BlueShield of Tennessee
Medical Policy
1 Cameron Hill Circle
Chattanooga, TN 37402